|
Pronunciation |
|
(pen
ta er ITH ri tole te tra NYE
trate) |
|
|
U.S. Brand
Names |
|
Duotrate®; Peritrate®;
Peritrate®
SA |
|
|
Generic
Available |
|
Yes |
|
|
Synonyms |
|
PETN |
|
|
Pharmacological Index |
|
Vasodilator |
|
|
Use |
|
Possibly effective for the prophylactic long-term management of angina
pectoris. Note: Not indicated to abort acute anginal
episodes. |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Hypersensitivity to pentaerythritol tetranitrate or other nitrates; severe
anemia; angle-closure glaucoma; postural hypotension; cerebral hemorrhage; head
trauma |
|
|
Warnings/Precautions |
|
Use with caution in patients with hypotension, hypovolemia, or increased
intracranial pressure. |
|
|
Adverse
Reactions |
|
>10%:
Cardiovascular: Flushing, postural hypotension
Central nervous system: Headache, lightheadedness, dizziness
Neuromuscular & skeletal: Weakness
1% to 10%: Dermatologic: Drug rash, exfoliative dermatitis
<1% (Limited to important or life-threatening symptoms): Nausea, vomiting,
methemoglobinemia (overdose) |
|
|
Drug
Interactions |
|
Alcohol (increased hypotension)
Aspirin (increases serum nitrate concentration)
Calcium channel blockers (increases hypotension)
Heparin's anticoagulant effect may be antagonized
Sildenafil: May cause severe hypotension; use is contraindicated.
|
|
|
Mechanism of
Action |
|
Stimulation of intracellular cyclic-GMP results in vascular smooth muscle
relaxation of both arterial and venous vasculature. Increased venous pooling
decreases left ventricular pressure (preload) and arterial dilatation decreases
arterial resistance (afterload). Therefore, this reduces cardiac oxygen demand
by decreasing left ventricular pressure and systemic vascular resistance by
dilating arteries. Additionally, coronary artery dilation improves collateral
flow to ischemic regions; esophageal smooth muscle is relaxed via the same
mechanism. |
|
|
Pharmacodynamics/Kinetics |
|
Onset of hemodynamic effect: Oral: Within 20-60 minutes
Duration: 4-5 hours, or up to 12 hours with the sustained release
formulations
Serum half-life: 10 minutes |
|
|
Usual Dosage |
|
Adults: Oral: 10-20 mg 4 times/day up to 40 mg 4 times/day before or after
meals and at bedtime; sustained release preparation 80 mg twice daily; use
lowest recommended doses in elderly initially; titrations up to 240 mg/day are
tolerated, however, headache may occur with increasing doses (reduce dose for a
few days; if headache returns or is persistent, an analgesic can be used to
treat symptoms) |
|
|
Dietary
Considerations |
|
Should be administered with glass of water on an empty
stomach |
|
|
Cardiovascular
Considerations |
|
Concomitant use of sildenafil (Viagra®) may precipitate
acute hypotension, myocardial infarction, or death. Nitrates used in right
ventricular infarction may induce acute hypotension. Nitrate use in severe
pericardial effusion may reduce cardiac filling pressure and precipitate cardiac
tamponade. |
|
|
Mental Health: Effects
on Mental Status |
|
May cause drowsiness |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Keep tablets in original tightly closed container; do not chew or crush
sustained release product |
|
|
Nursing
Implications |
|
Do not crush sustained release drug product
Monitor blood pressure reduction for maximal effect and orthostatic
hypotension |
|
|
Dosage Forms |
|
Capsule: sustained release: 15 mg, 30 mg
Tablet: 10 mg, 20 mg, 40 mg
Sustained release: 80 mg |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|